Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

Insulet公司（纳斯达克股票代码：PODD）的集团副总裁、首席会计官兼财务总监Lauren Budden最近出售了部分公司股份。Insulet是一家市值192亿美元的医疗设备公司，其股票在过去六个月内上涨了43%。根据最近的SEC文件显示，Budden于2024年12月10日以每股275.62美元的价格出售了915股Insulet普通股。此次交易的总价值为252,192美元。

From M&A and tariffs to new health leaders, here are the top issues for the medtech industry to watch when President-elect ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

The company said it had restarted production of intravenous solutions on two lines in November, and added they were manufacturing 1-liter IV solution bags, the most commonly used size by hospitals and ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Jury finds medical device company misappropriated secrets covering Insulet’s Omnipod l Insulet “extremely pleased” with ...